Autopsy report · NCT03858049

Efficacy and Safety of Crinone Versus Combination Medication (ACCESS)

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“The trend in LPS treatment tends to increase the dosage of progesterone in FET-HRT, this study was designed 5 years ago.”

The sponsor’s own words in the registry.

Life of this trial

Registered 3 months before it started.
Ran for about 2 years 5 months before it stopped.
172 participants enrolled.
Results were posted on the registry 2 years 5 months after it ended.

Vital statistics

Status: Terminated
Phase: Phase 4
Sponsor: Merck KGaA, Darmstadt, Germany
Sponsor type: Industry
Conditions: Infertility
Interventions: Crinone; Duphaston
Participants: 172
Sites: 1
Countries: China

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.